The Human ALK Gene Fusion and ROS1 Gene Fusion Combined Detection Kit uses RT-PCR technology to detect multiple ALK gene fusion types and ROS1 gene fusion types present in NSCLC using non-small cell lung cancer NSCLC sample RNA as the test object, thus assisting the clinic in selecting more comprehensively the NSCLC patients who can benefit from Crizotinib. It is suitable for use in NSCLC patients before entering targeted therapy, providing a scientific basis for individual drug administration in tumor patients.

Features: simple operation, easy to carry out; reliable results, intuitive interpretation; high sensitivity, sample saving, only 1-3 pieces of tumor tissue sections are required.

Applicable samples: fresh tissue, frozen tissue, paraffin-embedded tissue, etc.

ALK fusion genes and ROS1 fusion genes are the most common types of gene variants in non-small cell lung cancer. Various genes, such as EML4, KIF5B, TFG, and KLC1 can be fused with ALK genes, and SLC34A2, CD74, SDC4, EZR, TPM3, LRIG3, and GOPC can be fused with ROS1 genes. The occurrence of fusion activates signaling pathways associated with cell survival and proliferation, which in turn causes tumorigenesis.The incidence of ALK gene fusion and ROS1 gene fusion in NSCLC is 3-11% and 2-4%, respectively, and occurs most often in young, non-smoking patients with adenocarcinoma; the two fusions usually do not occur at the same time. The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines and the European Society for Medical Oncology (ESMO) Lung Cancer Consensus both clearly state that ALK and ROS1 gene fusion is an important biomarker for predicting the efficacy of ALK/ROS1 inhibitors, such as the targeted drug crizotinib (Xalkori®, Pfizer), and that ALK-positive or ROS1-positive non-small cell lung cancer ( NSCLC) patients can benefit from ALK/ROS1 inhibitor therapy.In February 2013, the State Food and Drug Administration (CFDA) approved crizotinib for the treatment of patients with locally advanced or metastatic NSCLC with ALK positivity as determined by a CFDA-approved assay.In March 2016, crizotinib received FDA approval for the treatment of ROS1 positive metastatic non-small cell lung cancer.